Primoris Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Primoris Therapeutics - overview
Established
2019
Location
Gwangmyeong, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2019 and based in Gwangmyeong, South Korea, Primoris Therapeutics operates as a biotechnology company that provides treatments for wounds, hair loss, and pneumonia using function-enhanced exosome technology. In February 2021, the firm raised KRW 3 billion in pre-series A funding from investors BNH Investment, DAYLI Partners, and Sneak Peek Investment. As of 2024, the company is headed by its CEO Na Gyu-Heum. Primoris Therapeutics offers a range of products centered around its drug delivery platforms.
These include exosomes and artificial nanovesicles designed for the delivery of therapeutic agents. The firm treatment area covers wound healing agents, pneumonia treatment, lung cancer treatment, and hair loss treatment. The company generates revenue through partnerships, investments, and the commercialization of its biopharmaceutical products.
Current Investors
BNH Investment, DAYLI Partners, Sneak Peek Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.primoris.co.kr
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Primoris Therapeutics - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | (500,502,000) | (1,027,833,000) | - | - | - |
| Operating Margin | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (468,731,000) | (961,048,000) | - | - | - |
| % Net Margin | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.